Medical devices, healthcare technology and the business of care
510(k) clearance · K251769

RevealAI-Lung

Precision Medical Ventures, Inc. Dba Revealdx · Decision date Jan 30, 2026

FDA DECISIONK251769

What did the FDA decide?

FDA records K251769 as a 510(k) premarket notification, with a decision dated Jan 30, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.

Regulatory pathway
510(k) premarket notification
Clinical specialty
Radiology
Decision date
Jan 30, 2026

FDA source record

Regulatory record facts

Identifier
K251769
Regulatory pathway
510(k) premarket notification
Product code
POK
Decision code
SESE
Decision date
Jan 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Computer-Assisted Diagnostic Software For Lesions Suspicious For Cancer.

Product code
POK
FDA device class
2

FDA decision timeline

  1. K251769 received

    Application receipt date recorded by FDA.

  2. K251769 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

Other records with product code POK

Product / regulatory recordCompanyPathwayDecision dateSource
BlineSlideK261679
Deep Breathe, Inc.510(k) clearanceOct 23, 2026FDA
Koios Medical, Inc.510(k) clearanceJul 2, 2026FDA
Sonio510(k) clearanceJun 4, 2026FDA
GE Medical Systems Ultrasound & Primary Care Diagnostics, LLC510(k) clearanceMar 27, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Precision Medical Ventures, Inc. Dba Revealdx

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Seattle, WA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records